Corporate bond markets are bracing for a $200 billion September as M&A activity and hyperscaler infrastructure spending drive a surge in high-grade debt issuance.
Oracle's 2055 notes trade at a steep discount with spreads nearly double pricing, indicating rising funding costs and investor caution.
Alphabet completed a $25 billion multi-tranche bond sale, and its long bonds traded below par amid heavy supply.
GlaxoSmithKline issued $6.5 billion in bonds to fund its Nuvalent acquisition, a sizable but routine M&A financing.
UBS priced a $6 billion bond offering, reflecting ongoing funding activity without notable spread stress.
AbbVie issued $10 billion in bonds to back M&A, part of a resurgence in acquisition funding.
HSBC Holdings priced a $6.75 billion bond offering, a large but standard funding event.
Martin Marietta Materials issued $5.5 billion in bonds to fund M&A, contributing to the uptick in acquisition financing.
US high-grade bond markets saw a massive $57 billion in issuance over two days following Labor Day, signaling a potential record-breaking September. While M&A-related financing is rebounding, investor sentiment remains cautious as seen in the widening spreads of long-dated AI-linked debt, including Oracle's 2055 notes.
Investors are demanding higher risk premiums due to shifting funding landscapes and concerns over long-term debt sustainability, causing spreads to widen from T+125 at issuance to T+245.
The surge is driven by a combination of pent-up demand following the summer lull, a resurgence in M&A-related financing, and ongoing capital requirements for AI infrastructure.